LEGAL PROCEEDINGS
−Removed: On July 2, 2020, we received a notice of investigation and subpoena to produce information and documents from the Division of Enforcement of the SEC.
−Removed: The subpoena seeks information and documents related to events and circumstances leading up to our March 17, 2020 announcement that we had commenced shipping samples of our COVID-19 IgG/IgM Rapid Test to countries outside of the United States, and had initiated the application process with the United States Food and Drug Administration under the COVID-19 Emergency Use Authorization for approval to market and sell the test in the United States.
−Removed: The subpoena also seeks information and documents about the identity of any persons who were aware of the substance of the March 17, 2020 announcement prior to that date, as well as certain corporate policies and documentation.
−Removed: We are cooperating and intend to continue cooperating fully with the SEC’s investigation.
−Removed: At this time, we are unable to predict the duration, scope or outcome of this investigation.
+Added: The Company is, from time to time, involved in legal proceedings, claims and litigation arising in the ordinary course of business.
+Added: While the amounts claimed may be substantial, the ultimate liability cannot presently be determined because of considerable uncertainties that exist.
+Added: Therefore, it is possible the outcome of such legal proceedings, claims and litigation could have a material effect on quarterly or annual operating results or cash flows when resolved in a future period.
+Added: We are not currently a party to any legal proceedings, not covered by insurance, that individually or in the aggregate, are deemed to be material to our financial condition or results of operations (see Note 9 to the consolidated financial statements).
+Added: On July 2, 2020, the Company received a notice of investigation and subpoena to produce information and documents from the Division of Enforcement of the SEC.
+Added: The subpoena requested information and documents related to events and circumstances leading up to the March 17, 2020 announcement that the Company had commenced shipping samples of the Company’s COVID-19 IgG/IgM Rapid Test to countries outside of the United States, and had initiated the application process with the United States Food and Drug Administration under the COVID-19 Emergency Use Authorization for approval to market and sell the test in the United States.
+Added: The subpoena also requested information and documents about the identity of any persons who were aware of the substance of the March 17, 2020 announcement prior to that date.
+Added: In addition, on December 15, 2020, the SEC sent a second subpoena related to this investigation to Zack Irani, the Company’s CEO, requesting documents held by Mr.
+Added: Irani concerning his past purchases of Company stock, any past communications with certain persons and entities, and other personal and Company documents.
+Added: The Company and Mr.
+Added: Irani have cooperated fully with the SEC’s investigation and provided information as requested.
+Added: At this time, the Company is unable to predict the duration, scope or outcome of these investigations.
+Added: We can provide no assurances as to the outcome of the SEC investigation.
MINE SAFETY DISCLOSURES
1 unchanged sentence
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.